Louis-Charles | Explaining Longevity Interventions | E-Book | www.sack.de
E-Book

E-Book, Englisch, 414 Seiten

Reihe: PublishDrive

Louis-Charles Explaining Longevity Interventions

The Evidence Behind NAD+, Rapamycin, Metformin, and More
1. Auflage 2026
ISBN: 979-8-90498-249-2
Verlag: PublishDrive
Format: EPUB
Kopierschutz: 0 - No protection

The Evidence Behind NAD+, Rapamycin, Metformin, and More

E-Book, Englisch, 414 Seiten

Reihe: PublishDrive

ISBN: 979-8-90498-249-2
Verlag: PublishDrive
Format: EPUB
Kopierschutz: 0 - No protection



The longevity intervention landscape is louder than it has ever been. NAD+ precursors are on billboards. Rapamycin has moved from the clinical margins to the podcast mainstream. Metformin is discussed at dinner parties by adults who do not have diabetes. Senolytics are being sold as supplements before the human trials are complete. GLP-1 receptor agonists have gone from a niche diabetes and obesity intervention to a suspected longevity drug with an audience that keeps growing. Each of these interventions has serious biology behind it. Each also sits inside a marketing environment that is not honest about the state of the evidence.
Explaining Longevity Interventions is volume five of The Longevity Code Series, and it opens with a framework, not a supplement. The first chapter is a five-question rubric for evaluating any longevity claim: What is the proposed mechanism? What does the animal model evidence show? What do the human trials actually show, and what were their endpoints? What is the safety profile? And what is being marketed on top of the evidence, versus what the evidence supports? A reader who works through those five questions on any intervention-one in this book or one that has not been invented yet-is protected from most of what the longevity marketplace is trying to sell them.
Chapters then walk through the interventions with the strongest data behind them. NAD+ precursors, and the running debate between nicotinamide riboside and nicotinamide mononucleotide. Rapamycin and mTOR inhibition, with an honest look at the dosing schedules being investigated for longevity indications versus the transplantation regimens the drug was originally developed for. Metformin and the TAME trial. Senolytics, and the biology of clearing the senescent cells that accumulate with age. GLP-1 receptor agonists, and the emerging longevity signals that make oncologists, cardiologists, and gerontologists watch the same drug class with the same interest. And the smaller-evidence-base candidates now attracting research attention: hyperbaric oxygen, plasma exchange, epigenetic reprogramming, and the frontier of the field.
Each chapter walks through the mechanism, the animal-model evidence, the human trial data, the safety profile, and the honest state of what is known and unknown. Every claim is anchored in peer-reviewed evidence. The book is honest about where the enthusiasm has raced ahead of the trials.
This book is not medical advice, and it is not a protocol. It is the foundation for every conversation the reader will have with a clinician about their own longevity plan. Read on when you are ready. The reader who understands the framework will never again mistake a marketing budget for a mechanism of action.

Louis-Charles Explaining Longevity Interventions jetzt bestellen!

Autoren/Hrsg.


Weitere Infos & Material


The Gold Standard, Exercise as the Benchmark Intervention


Readers of Book 2 in this series, on exercise and aging, will recognize the mechanistic scaffolding that underpins this chapter. The BDNF, VEGF, PGC-1alpha, and AMPK pathways developed in that volume reappear here in the specifically longevity-benchmark framing, and the weekly minute and intensity targets this chapter arrives at- roughly 150 minutes of moderate aerobic activity plus two resistance sessions per week- are the same targets Book 2 established through the broader physiological literature. If you have already worked through Book 2, treat this chapter as the longevity-specific application of the framework you already know. If you have not, this chapter still stands alone, though the earlier volume develops the underlying mechanistic biology in more depth.

Dr. Sarah Chen is 52, a sports medicine physician in Denver whose clinical practice focuses on performance medicine for master athletes, recreational runners, cyclists, and triathletes in their forties and fifties who want to keep training seriously into their sixties and beyond. She was recently invited to join the advisory board of a new longevity clinic opening downtown, and she has spent the past week working through the client protocol document they sent her in preparation for the call. The protocol is, in its own way, impressive. It includes rapamycin on an intermittent low-dose schedule, NMN, metformin, a comprehensive quarterly biomarker panel, and a nutritional framework built around time-restricted eating. Together, these sections run twenty-two pages. The exercise section runs less than one page. It consists of two sentences recommending "regular aerobic activity" and "strength training," with no specific programming, progression scheme, or monitoring plan.

Sarah has read that one page more times than she can count this week, and her frustration has grown with each pass. She has scheduled a call with the clinic's founders to make one argument before she decides whether to put her name on their advisory board: no pharmacological intervention belongs in a longevity protocol until exercise has been optimized, monitored, and programmed with at least the same rigor being applied to the pharmacology. She is not anti-drug, and she is not dismissing rapamycin, NMN, or metformin as unworthy of study. Her argument is narrower and, she believes, harder to dispute: the longevity clinic world has its proportions backward, lavishing its most elaborate protocols and highest price tags on the interventions with the thinnest human evidence, while treating the intervention with the deepest evidence base, the largest measured effect sizes, and the broadest biological reach as an afterthought.

What makes Sarah particularly well positioned to make this argument is the specific patient population she treats every week. A master's athlete who arrives in her clinic after a decade of consistent training and who is now asking about rapamycin or NMN is, in effect, asking whether a pharmacological intervention can meaningfully add to a biological foundation that is already unusually well optimized. This is a genuinely different question from the one facing a sedentary 55-year-old considering the same compounds, and Sarah has noticed that longevity clinic marketing rarely distinguishes between these two very different starting points. In her clinical judgment, a protocol document that gives equal billing to pharmacology regardless of a client's underlying exercise status is missing the single most important variable determining how much benefit that pharmacology could plausibly add.

This chapter lays out Sarah's argument fully and grounds it in the strongest data currently available. By the end, the case for why "I exercise regularly" is not a sufficient answer, what an evidence-supported exercise foundation actually requires, and why no honest evaluation of any pharmacological longevity intervention can begin anywhere other than here should be difficult to argue against.

At the outset, it is worth stating what this chapter is not attempting to do. It is not attempting to convince a reader who already exercises consistently that they need to do more, and it is not building toward a claim that exercise alone is sufficient for optimal longevity outcomes at every stage of life. It is building toward a specific, falsifiable comparative claim: given the evidence available in 2026, exercise's effect size and evidence quality exceed those of every pharmacological longevity candidate examined later in this book, and any honest longevity strategy should reflect that fact in how it allocates attention, monitoring, and resources. This is a claim about proportionality, not a claim that pharmacology is irrelevant, and keeping that distinction clear will make the comparative data in the sections ahead considerably more useful.

Why Exercise Earns the Strong Evidence Tier


Applying the four-level evidence ranking system from Chapter 1 to exercise produces an almost uncomfortable contrast with the compounds covered in the chapters ahead. Multiple large prospective cohort studies have documented exercise's relationship to all-cause mortality, some following participants for more than four decades, with dose-response relationships that track cleanly across intensity, duration, and, most tellingly, measured fitness level rather than merely self-reported activity. This combination- size, duration, replication across independent cohorts on different continents, and a graded dose-response pattern that is one of the classic signatures epidemiologists look for when trying to distinguish a causal relationship from a confounded one- is precisely what places an intervention in the strong tier.

No pharmacological longevity candidate discussed in this book can currently make the same claim, and that is not a rhetorical flourish; it is a direct comparison of evidentiary architecture. Rapamycin's human longevity evidence, examined fully in Chapter 5, consists of short-duration safety and biomarker trials, not decades-long mortality data. NAD+ precursor trials, examined in Chapter 4, are smaller, shorter, and rely on biomarker surrogates whose validation is considerably weaker than the biomarkers used in the largest exercise cohorts. This is the comparison baseline Sarah wants the longevity clinic's founders to sit with before they finalize twenty-two pages of pharmacology and less than one page of movement.

The scale difference between these evidence bases deserves to be stated in concrete terms rather than left as a vague impression. Taken together, the exercise cohorts referenced throughout this chapter represent data from several hundred thousand individuals followed for periods ranging from a decade to more than forty years, with mortality as the measured endpoint rather than a proxy. By contrast, the largest completed human trials of rapamycin analogs in aging-related contexts have enrolled at most a few hundred participants and followed them for months rather than decades, measuring immune function or biomarker outcomes rather than survival. NAD+ precursor trials are smaller still, typically enrolling several dozen to a few hundred participants over trial periods measured in weeks to a few months. This is not a criticism of the researchers running those trials, who are working within the genuine constraints on funding, feasibility, and regulatory pathways available to them for a compound not yet approved for a longevity indication. It honestly describes where each evidence base currently stands, and Sarah's argument depends on the reader holding these two very different scales of evidence side by side rather than treating a well-designed but modest-sized pharmacological trial as though it carries the same evidentiary weight as a forty-year mortality cohort.

Sarah's clinical experience gives her a useful vantage point on this contrast that many longevity clinic founders, who often come from backgrounds in biochemistry, internal medicine, or entrepreneurship rather than sports medicine specifically, may not share as directly. Her master's athlete patients arrive already exercising seriously, and her job is to fine-tune training load, recovery, and injury prevention in a population that has already captured most of exercise's longevity benefit by training consistently for years. When she looks at a longevity clinic protocol that treats exercise as a settled, minor detail while building an elaborate structure of monitoring and intervention around comparatively unproven pharmacology, she is seeing the inversion of her own daily clinical priorities. This chapter exists because that inversion, in her professional judgment, is less a matter of taste than a misreading of the actual evidence hierarchy.

The replication pattern behind exercise's evidence base deserves further emphasis, because replication, more than any single study's size, gives an evidence base its durability. The Cooper Clinic cohort was built primarily from a relatively affluent, health-engaged population visiting a preventive medicine clinic in Texas. The HUNT Study drew from a broad, largely unselected population in rural Norway with universal healthcare access and entirely different lifestyle patterns. Later UK Biobank-scale analyses drew from a large, geographically and socioeconomically diverse population across the United Kingdom. That a similar graded relationship between fitness and mortality risk emerges across three such different populations, different healthcare systems, different eras of medical practice, and different measurement approaches to fitness is a form of evidence robustness that a single trial, however large, cannot provide on its own. This same replication standard, cross-population, cross-method consistency, is precisely what the pharmacological...



Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.